ID   FE-PD
AC   CVCL_H614
SY   FEPD; FePD
DR   BTO; BTO:0005005
DR   cancercelllines; CVCL_H614
DR   Cell_Model_Passport; SIDM01496
DR   ChEMBL-Cells; CHEMBL3307722
DR   ChEMBL-Targets; CHEMBL614866
DR   Cosmic; 1086362
DR   Cosmic; 2013354
DR   Cosmic; 2024370
DR   Cosmic; 2402467
DR   Cosmic; 2674500
DR   Cosmic; 2814459
DR   DepMap; ACH-001068
DR   GEO; GSM1217152
DR   GEO; GSM2527948
DR   Progenetix; CVCL_H614
DR   PubChem_Cell_line; CVCL_H614
DR   Wikidata; Q54834716
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8035614;
RX   PubMed=8558920;
RX   PubMed=15356658;
RX   PubMed=16596703;
RX   PubMed=26657151;
RX   PubMed=28356514;
RX   PubMed=29533902;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 56 hours (PubMed=8035614).
CC   Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Gly1097Val (c.3290_3291delinsTT); Zygosity=Unspecified (PubMed=28356514).
CC   Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Gly618Arg (c.1852G>C); ClinVar=VCV001192236; Zygosity=Unspecified (PubMed=28356514).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Originally the patient was suffering from Hodgkin lymphoma.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C37194; Anaplastic large cell lymphoma, ALK-negative
DI   ORDO; Orphanet_300903; ALK-negative anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 21
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8035614;
RA   Del Mistro A., Leszl A., Bertorelle R., Calabro M.L., Panozzo M.,
RA   Menin C., D'Andrea E., Chieco-Bianchi L.;
RT   "A CD30-positive T cell line established from an aggressive anaplastic
RT   large cell lymphoma, originally diagnosed as Hodgkin's disease.";
RL   Leukemia 8:1214-1219(1994).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=15356658; DOI=10.1038/sj.leu.2403465;
RA   Drexler H.G., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   anaplastic large-cell lymphoma.";
RL   Leukemia 18:1569-1571(2004).
//
RX   PubMed=16596703; DOI=10.1002/pmic.200500647;
RA   Cussac D., Pichereaux C., Colomba A., Capilla F., Pont F.,
RA   Gaits-Iacovoni F., Lamant L., Espinos E., Burlet-Schiltz O.,
RA   Monsarrat B., Delsol G., Payrastre B.;
RT   "Proteomic analysis of anaplastic lymphoma cell lines: identification
RT   of potential tumour markers.";
RL   Proteomics 6:3210-3222(2006).
//
RX   PubMed=26657151; DOI=10.1038/onc.2015.456;
RA   Ceccon M., Merlo M.E.B., Mologni L., Poggio T., Varesio L.M.,
RA   Menotti M., Bombelli S., Rigolio R., Manazza A.D., Di Giacomo F.,
RA   Ambrogio C., Giudici G., Casati C., Mastini C., Compagno M.,
RA   Turner S.D., Gambacorti-Passerini C., Chiarle R., Voena C.;
RT   "Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and
RT   drug dependency.";
RL   Oncogene 35:3854-3865(2016).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//